The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Addressing limitations in mRNA profiling for metastatic colorectal cancer
Marco Germani, MD, FRCP, University of Pisa, Pisa, Italy, highlights the challenges associated with mRNA profiling in metastatic colorectal cancer (mCRC), noting its limited consistency across trials and cohorts. Variations in methodologies and the selected panels can lead to discrepancies in results. Using a standardized approach with fewer genes may enhance consistency and reliability in evaluating mRNA profiling, paving the way for more effective biomarkers in clinical practice. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
